NCT01459328Unknown3 期
Resource-Sparing Curative Treatment for Rectal Cancer
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 350
- 试验地点
- 22
- 主要终点
- Overall Survival
研究概览
简要总结
This is a prospective, multicentre, randomized clinical trial comparing two different neo-adjuvant radiation-based strategies prior to intended surgery for locally advanced adenocarcinoma of the rectum.
This trial may establish the investigational therapy to be superior to, or at least not inferior to conventional treatment.
详细描述
This phase III randomised clinical trial compares the outcome of two different neo-adjuvant radiation based treatments for locally advanced rectal carcinoma. This encompasses patients at risk for a positive circumfrential resection margin (CRM+) on baseline assessment imaging and pateints identified as being with a T-descriptor T4 at baseline assessment.
The arms compared are as follows:
- The investigational arm: short chemo-radiation course(25Gy in 5 daily fractions over 1 week) +/- surgery.
- The conventional arm: protracted chemo-radiation course (50Gy in 25 daily fractions over 5 weeks combined with chemotherapy)+/- surgery.
The outcomes include four domains: overall survival, biological effect, quality of life and health-related economics.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age or older
- •Clinical (i.e. surgical determination) and/or diagnostic image findings consistent with c/uT4 or CRM+ (note that CRM+ must be established by MRI), primary rectal Adenocarcinoma (i.e. histology consistent with origin from rectal mucosa); these constitute LARC for the purpose of this protocol
- •Treatment will be directed at the primary cancer, being clinically appropriate and given with an initial intent to cure the patient (this includes accepting up front that radiation and surgery are feasible; for surgery, this means that the patient has been determined fit for major surgery by an anaesthesiologist prior to the request for randomization)
- •Performance status is sufficient to undertake the treatment in either arm (KPS>50%)
- •Patient is accessible for required follow-up and data collection
- •Radiation oncologist expects survival to exceed 6 months from date of diagnosis
- •Patient provides informed consent
排除标准
- •Recurrent rectal cancer
- •Primary wholly in the sigmoid colon
- •Considered to be arising in the anal canal
- •Metastatic disease beyond the pelvis (by clinical assessment and/or diagnostic imaging)
- •Contraindications to protocol RT or to protocol chemotherapy, such as one or more of the following:
- •any prior RT to the pelvis; a solitary pelvic kidney within the intended radiation volume
- •consideration by the most responsible radiation oncologist that the treatment volume is too large, or the amount of small bowel or other critical organs within the treatment volume is too much for safe treatment
- •significantly abnormal laboratory tests such as impaired renal/liver function
- •a haemoglobin that is < 8.0 (or 80, SI) and the patient is not transfused to exceed 8.0 (or 80, SI)
- •on-going medications that are not compatible with protocol neo-adjuvant chemotherapy as described in this protocol
- •Significant development issues (such as with age < 18 yr)
- •Co-morbidity
- •Psychiatric diagnosis
- •Physical impairment
- •Pregnancy or continuing breast-feeding, that precludes administration of protocol treatments, or that precludes data collection (such as likely to preclude follow-up visits or completing questionnaires)
结局指标
主要结局
Overall Survival
时间窗: From commencement of radiation (day 1) to death or last follow-up up to 5 years.
次要结局
- Biological Effect and Tumour Biology(Prior to surgical decision in weeks 13-15 and 4 weeks after surgery)
- Quality of Life(From date of randomization till the end of follow-up (5 years))
- Health-related Economics(From date of randomization till the end of follow-up (5 years))
研究者
研究点 (22)
Loading locations...
相似试验
已完成
不适用
A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node MetastasisLymph Node MetastasisCancer of Rectum and AnusOxaliplatinIntestinal NeoplasmsGastrointestinal NeoplasmsRectal DiseasesRectal NeoplasmsNCT06048146Cancer Institute and Hospital, Chinese Academy of Medical Sciences180
Unknown
不适用
Extralevator Versus Standard Abdominoperineal Resection For Rectal AdenocarcinomaRectal AdenocarcinomaNCT01702116Stony Brook University34
Unknown
4 期
Total Neoadjuvant Therapy in Rectal Cancer TreatmentRectal CancerNCT04747951State Scientific Centre of Coloproctology, Russian Federation280
已完成
3 期
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal CancerColorectal CancerNCT00726622Alliance for Clinical Trials in Oncology486
已完成
不适用
Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for FailureRectal CancerNCT04679597Institute of Oncology Ljubljana161